Related references
Note: Only part of the references are listed.Interaction Entropy for Computational Alanine Scanning
Yuna Yan et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2017)
Interaction entropy for protein-protein binding
Zhaoxi Sun et al.
JOURNAL OF CHEMICAL PHYSICS (2017)
Interaction Entropy: A New Paradigm for Highly Efficient and Reliable Computation of Protein-Ligand Binding Free Energy
Lili Duan et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2016)
The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities
Samuel Genheden et al.
EXPERT OPINION ON DRUG DISCOVERY (2015)
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases
Luc J. Farmer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Targeting substrate- site in Jak2 kinase prevents emergence of genetic resistance
Meenu Kesarwani et al.
SCIENTIFIC REPORTS (2015)
PDB-wide collection of binding data: current status of the PDBbind database
Zhihai Liu et al.
BIOINFORMATICS (2015)
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
Elisa Rumi et al.
BLOOD (2014)
Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set
Huiyong Sun et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2014)
JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis
Leeyen Hsu et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2014)
The Janus Kinase 2 Inhibitor Fedratinib Inhibits Thiamine Uptake: A Putative Mechanism for the Onset of Wernicke's Encephalopathy
Qiang Zhang et al.
DRUG METABOLISM AND DISPOSITION (2014)
2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors
Michael Siu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Lead identification of novel and selective TYK2 inhibitors
Jun Liang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2
Mark Zak et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis
Kris Vaddi et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2
Mark Zak et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors
Emily J. Hanan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors
Janusz J. Kulagowski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Ruxolitinib
Ruben A. Mesa et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations
Tingjun Hou et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
Discovery of 1-Amino-5H-pyrido[4,3-b]indol-4-carboxamide Inhibitors of Janus Kinase 2 (JAK2) for the Treatment of Myeloproliferative Disorders
Jongwon Lim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors
Tiansheng Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2
Mark W. Ledeboer et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Fragment-based discovery of JAK-2 inhibitors
Stephen Antonysamy et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Janus Kinase 2 Inhibitors. Synthesis and Characterization of a Novel Polycyclic Azaindole
Tiansheng Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders
Elizabeth O. Hexner et al.
BLOOD (2008)
Jak2: normal function and role in hematopoietic disorders
James N. Ihle et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)
Characterization of murine JAK2V617F-positive myeloproliferative disease
Thomas G. P. Bumm et al.
CANCER RESEARCH (2006)
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
Gerlinde Wernig et al.
BLOOD (2006)
JAK2(V617F) expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis
Catherine Lacout et al.
BLOOD (2006)
The Amber biomolecular simulation programs
DA Case et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2005)
The PDBbind database: Collection of binding affinities for protein-ligand complexes with known three-dimensional structures
RX Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Signaling through the JAK/STAT pathway, recent advances and future challenges
T Kisseleva et al.
GENE (2002)
Share Paper
